Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens.

McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW.

Mol Endocrinol. 1995 Jun;9(6):659-69.

PMID:
8592512
2.
3.
4.

Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.

Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. Review.

PMID:
11162936
5.

Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.

Poulin R, Merand Y, Poirier D, Levesque C, Dufour JM, Labrie F.

Breast Cancer Res Treat. 1989 Oct;14(1):65-76.

PMID:
2605344
6.

Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists.

Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W.

Proc Natl Acad Sci U S A. 1995 May 9;92(10):4206-10.

8.

Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.

Levenson AS, Catherino WH, Jordan VC.

J Steroid Biochem Mol Biol. 1997 Mar;60(5-6):261-8.

PMID:
9219916
9.
12.

Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity.

Fan JD, Wagner BL, McDonnell DP.

Mol Endocrinol. 1996 Dec;10(12):1605-16. Erratum in: Mol Endocrinol 1997 Mar;11(3):341.

PMID:
8961270
13.

A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.

Catherino WH, Wolf DM, Jordan VC.

Mol Endocrinol. 1995 Aug;9(8):1053-63.

PMID:
7476979
14.
16.

Antiestrogens: mechanisms and actions in target cells.

Katzenellenbogen BS, Montano MM, Le Goff P, Schodin DJ, Kraus WL, Bhardwaj B, Fujimoto N.

J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):387-93.

PMID:
7626486
17.

Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins.

Logie C, Nichols M, Myles K, Funder JW, Stewart AF.

Mol Endocrinol. 1998 Aug;12(8):1120-32.

PMID:
9717838
18.

Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta.

Paige LA, Christensen DJ, Grøn H, Norris JD, Gottlin EB, Padilla KM, Chang CY, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM.

Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3999-4004.

19.

Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo.

Metzger D, Berry M, Ali S, Chambon P.

Mol Endocrinol. 1995 May;9(5):579-91.

PMID:
7565805
Items per page

Supplemental Content

Support Center